RenovoRx highlights case study on intra-arterial gemcitabine delivery via TAMP in pancreatic cancer

• RenovoRx highlighted a newly published peer-reviewed case study on its TAMP platform using RenovoCath to deliver gemcitabine for locally advanced pancreatic cancer.
• Results have already been presented via publication in Radiology Case Reports, not flagged for a future medical meeting.
• The report showed the procedure was completed without complications, supporting feasibility of localized intra-arterial delivery versus standard IV chemotherapy.
• Imaging suggested disease control on conventional scans, while metabolic imaging indicated a treatment response, pointing to PET-CT as a better monitoring tool.
• The case also showed physicians could manage challenging anatomy during the same session, potentially widening the addressable patient pool for the approach.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.